TY - JOUR
T1 - Therapeutic intervention with breast cancer metastasis
AU - Chelouche Lev, Dina
AU - Price, Janet E.
PY - 2002
Y1 - 2002
N2 - Metastatic disease, mainly to the lungs, liver, bone, and brain, is the most common cause of death from breast cancer, despite advances in surgical and clinical management. Two basic principles govern the process of metastasis. First, that tumors are heterogeneous populations of cells, and second, that the process is a sequence of events that depends on tumor cell properties and interactions with the microenvironment at the site of metastasis. Inhibitors targeted at any of these different steps have the potential to inhibit metastatic progression, and examples of key therapeutic targets include overexpression of growth factor receptors, angiogenic factors, matrix metalloproteases, and integrin receptors. The identification of molecular targets for therapy of breast cancer metastasis will be accelerated by DNA array technology, and their selection for use should include evaluation of interactions between tumor cells and normal tissue components. These sorts of inhibitors are likely to target both cancer and normal cell functions, for example, inhibitors of matrix metalloproteases that can potentially inhibit both tumor cell invasion and angiogenesis. The use of appropriate animal models will be necessary to determine the impact of targeted inhibitors on the growth and development of breast cancer metastasis.
AB - Metastatic disease, mainly to the lungs, liver, bone, and brain, is the most common cause of death from breast cancer, despite advances in surgical and clinical management. Two basic principles govern the process of metastasis. First, that tumors are heterogeneous populations of cells, and second, that the process is a sequence of events that depends on tumor cell properties and interactions with the microenvironment at the site of metastasis. Inhibitors targeted at any of these different steps have the potential to inhibit metastatic progression, and examples of key therapeutic targets include overexpression of growth factor receptors, angiogenic factors, matrix metalloproteases, and integrin receptors. The identification of molecular targets for therapy of breast cancer metastasis will be accelerated by DNA array technology, and their selection for use should include evaluation of interactions between tumor cells and normal tissue components. These sorts of inhibitors are likely to target both cancer and normal cell functions, for example, inhibitors of matrix metalloproteases that can potentially inhibit both tumor cell invasion and angiogenesis. The use of appropriate animal models will be necessary to determine the impact of targeted inhibitors on the growth and development of breast cancer metastasis.
KW - Angiogenesis
KW - Animal models
KW - Growth factor receptors
KW - Invasion
KW - Tumor-host interactions
UR - http://www.scopus.com/inward/record.url?scp=0141828921&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141828921&partnerID=8YFLogxK
U2 - 10.1615/CritRevEukaryotGeneExpr.v12.i2.40
DO - 10.1615/CritRevEukaryotGeneExpr.v12.i2.40
M3 - Review article
C2 - 12434927
AN - SCOPUS:0141828921
SN - 1045-4403
VL - 12
SP - 137
EP - 150
JO - Critical Reviews in Eukaryotic Gene Expression
JF - Critical Reviews in Eukaryotic Gene Expression
IS - 2
ER -